Metformin in Gestational Diabetes The Offspring Follow Up (MiGTOFU): Associations between maternal characteristics and size and adiposity of boys and girls at nine years.
Janet Alison RowanElaine Carolyn RushLindsay Dudley PlankPublished in: The Australian & New Zealand journal of obstetrics & gynaecology (2023)
Data from 98 women recruited in the Metformin in Gestational Diabetes trial and dual-energy X-ray absorptiometry studies of their children at nine years were analysed to investigate associations between maternal measures during pregnancy and their children's size and adiposity. Mothers of boys (n = 56) and girls (n = 42) had been randomised to metformin or insulin treatment at 30.1 ± 2.8 and 29.3 ± 4.1 weeks gestation, respectively. In boys, fat-free mass indexed to height squared was associated with maternal weight, body mass index, maternal glycaemia and metformin treatment. In boys and girls, fat mass indexed to height squared was associated with maternal glycaemia measures before gestational diabetes treatment.
Keyphrases
- pregnancy outcomes
- body mass index
- dual energy
- birth weight
- weight gain
- computed tomography
- clinical trial
- type diabetes
- young adults
- adipose tissue
- pregnant women
- insulin resistance
- study protocol
- gestational age
- physical activity
- open label
- mass spectrometry
- preterm infants
- polycystic ovary syndrome
- weight loss
- magnetic resonance
- combination therapy
- preterm birth
- big data
- high fat diet
- skeletal muscle
- phase ii
- fatty acid
- postmenopausal women